OBI Pharma Inc. to attend the investor conference on new drug development, hosted by Masterlink SecuritiesJanuary 5, 2018
FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)January 17, 2018
- Defendant: Reporter Pei amongst the other six reporters
- Name of the legal agency or court: Taiwan Shilin District Court
- Reference/case numbers of relevant documents: 2017 Sheng Pan Zi, No. 72
- Date of occurrence of the event: January 8, 2018
- Background and circumstances of the matter (including the property/subject matter under dispute): The company received Shilin District Court’s decision for the denial of OBI’s request to submit the case for trial.
- Course and progression of handling of the matter: The company will consult its legal counsel on appropriate legal responses.
- Effect on company finances and business and estimated monetary amount of the effect: The business operation and financial status of the company are normal.
- Countermeasures and status of amelioration: None
- Any other matters that need to be specified: N